Astellas Pharma Inc. (TYO:4503)
Japan flag Japan · Delayed Price · Currency is JPY
2,417.00
+27.50 (1.15%)
Sep 3, 2026, 3:30 PM JST

Astellas Pharma Balance Sheet

Millions JPY. Fiscal year is Apr - Mar.

Assets

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash & Equivalents
244,698281,605188,372335,687376,840315,986
Cash & Short-Term Investments
244,698281,605188,372335,687376,840315,986
Cash Growth
13.60%49.49%-43.89%-10.92%19.26%-3.11%
Accounts Receivable
831,701746,808632,525534,985427,965382,462
Other Receivables
13,10214,95513,69113,05117,81321,539
Receivables
844,803761,763646,216548,036445,778404,001
Inventory
337,887331,014297,261248,738174,386153,072
Other Current Assets
58,21147,54169,50062,26952,95050,295
Total Current Assets
1,485,5991,421,9231,201,3491,194,7301,049,954923,354
Property, Plant & Equipment
363,614358,424328,921293,742286,459269,044
Long-Term Investments
20,504202,001172,239163,018145,028141,206
Goodwill
450,475441,175415,207418,694328,411303,030
Other Intangible Assets
1,022,695996,9321,123,7141,453,824562,496623,431
Long-Term Deferred Tax Assets
146,271146,58898,11345,59484,16972,331
Other Long-Term Assets
203,368-1111-1
Total Assets
3,692,5263,567,0423,339,5443,569,6032,456,5182,332,395

Liabilities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Accounts Payable
192,286199,752187,840185,193140,236130,739
Accrued Expenses
-193,886169,119155,233143,817136,553
Short-Term Debt
30,000-184,874420,39375,00090,000
Current Portion of Long-Term Debt
239,870245,95281,65851,885-50,000
Current Portion of Leases
-17,61516,33514,94413,54617,730
Current Income Taxes Payable
43,41068,93434,54938,5155,13732,388
Other Current Liabilities
729,190492,262387,235419,562348,298230,001
Total Current Liabilities
1,234,7561,218,4011,061,6101,285,725726,034687,411
Long-Term Debt
320,000320,000564,893449,93754,217676
Long-Term Leases
-88,78689,32670,75661,46155,014
Pension & Post-Retirement Benefits
21,57421,47322,74624,67424,81837,226
Long-Term Deferred Tax Liabilities
3,0351,2755,35351,3466,0485,823
Other Long-Term Liabilities
168,71286,22382,36191,17775,98685,937
Total Liabilities
1,748,0771,736,1581,826,2891,973,615948,564872,087

Shareholders' Equity

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Common Stock
103,001103,001103,001103,001103,001103,001
Additional Paid-In Capital
181,698185,162185,259184,070181,280179,467
Retained Earnings
976,692902,836740,939809,400908,158944,261
Treasury Stock
-31,656-34,945-37,524-33,783-25,123-13,934
Comprehensive Income & Other
712,951672,990521,580533,300340,638247,513
Total Common Equity
1,942,6861,829,0441,513,2551,595,9881,507,9541,460,308
Minority Interest
1,7631,840----
Shareholders' Equity
1,944,4491,830,8841,513,2551,595,9881,507,9541,460,308
Total Liabilities & Equity
3,692,5263,567,0423,339,5443,569,6032,456,5182,332,395

Additional Metrics

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Jun '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Total Debt
589,870672,353937,0861,007,915204,224213,420
Net Cash (Debt)
-345,172-390,748-748,714-672,228172,616102,566
Net Cash Growth
----68.30%116.09%
Net Cash Per Share
-192.05-217.43-416.61-373.5394.5855.42
Filing Date Shares Outstanding
1,7931,7911,7901,7931,7971,827
Total Common Shares Outstanding
1,7931,7911,7901,7931,7971,827
Working Capital
250,843203,522139,739-90,995323,920235,943
Book Value Per Share
1083.481020.96845.25890.07839.26799.26
Tangible Book Value
469,516390,937-25,666-276,530617,047533,847
Tangible Book Value Per Share
261.86218.22-14.34-154.22343.42292.19